首页> 美国卫生研究院文献>Allergy Asthma and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology >Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score
【2h】

Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score

机译:氯雷他定片在环境暴露单位中对豚草花粉挑战的成人季节性过敏性鼻炎的症状控制的症状发作:总症状评分的事后分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundLoratadine is a second-generation, non-sedating antihistamine used for the relief of allergic rhinitis symptoms. Previous studies reported that when loratadine was encapsulated, the onset of action for symptom relief was 180 min. However, unmodified loratadine tablets were not evaluated at that time. Using data from a previously published Environmental Exposure Unit (EEU) study comparing azelastine nasal spray with loratadine tablets, cetirizine tablets, and placebo, this post hoc analysis determines the onset of action of loratadine tablets (i.e. unmodified) by analyzing the total symptom score for the relief of nasal and ocular seasonal allergic rhinitis (SAR) symptoms.
机译:背景氯雷他定是用于缓解过敏性鼻炎症状的第二代非镇静抗组胺药。先前的研究报告说,将氯雷他定包封时,缓解症状的起效时间为180分钟。但是,当时未评估未修饰的氯雷他定片。使用先前发表的环境暴露单位(EEU)研究中的数据比较氮卓斯汀鼻喷雾剂与氯雷他定片,西替利嗪片和安慰剂的比较,这项事后分析通过分析总症状评分确定氯雷他定片的作用发作(即未改变)。缓解鼻和眼季节性过敏性鼻炎(SAR)症状。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号